Complex Scenarios in Advanced Melanoma: Examining Three Patient Cases
February 8th 2017Despite significant developments on the advanced melanoma treatment front, “many clinical scenarios remain where there is no clear-cut course of action," said Robert H.I. Andtbacka, MD, CM, during a recent OncLive Peer Exchange®.
Nab-Paclitaxel Paired With Anti-PD-L1 Immunotherapies in TNBC Studies
February 8th 2017Combination regimens that pair nab-paclitaxel with PD-L1 checkpoint blockade immunotherapy agents are emerging as a robust area of investigation in triple-negative breast cancer, bolstered by clinical trial results that establish the chemotherapeutic agent as an effective partner for other therapies.
Liquid Biopsies Making Impact in Lung Cancer, Other Tumor Types
February 5th 2017The noninvasive testing that has long been the goal of solid tumor analysis is making its presence felt in lung cancer, and other malignancies likely will not be far behind, experts say. Although many potential uses for liquid biopsies are envisioned, much work remains to be done to establish the clinical utility of these tests.
Enhanced Recovery Program Improves Outcomes After Colorectal Cancer Surgery
February 3rd 2017The adoption of enhanced recovery after surgery protocols can improve not only the outcomes of patients after a procedure but can also reduce hospital costs, as has been seen in an ERAS program in colorectal cancer at the University of Virginia Health System.
Practicing Oncology in the Gray Zone
February 1st 2017"Uncertainty" is a routine dilemma when discussing a prognosis with a patient with cancer and his or her family. The prognosis is, at best, a statistical probability—assuming the available objective data are somewhat representative of the individual patient.